Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/15/2024 | $7.00 → $5.00 | Buy → Hold | Craig Hallum |
| 8/6/2024 | Overweight → Equal-Weight | Morgan Stanley | |
| 8/6/2024 | Buy → Neutral | BTIG Research | |
| 8/6/2024 | Overweight → Neutral | JP Morgan | |
| 6/21/2024 | $7.50 | Buy | Craig Hallum |
| 12/14/2023 | Neutral | Guggenheim | |
| 7/5/2023 | $18.00 | Overweight | JP Morgan |
| 2/2/2023 | $14.00 | Buy | UBS |
MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we
It is Deeply Disturbing, in Kent Lake's View, that the Company's Amended Agreement to Merge with Akoya Deprives Quanterix Shareholders of Ability to Vote on the Transaction Believes Quanterix's Maneuvers Further Demonstrate the Need for New Directors with Real Credibility and Accountability to Shareholders – And Will Press on With Nominations of Three Highly Qualified Board Candidates Kent Lake PR LLC ("Kent Lake"), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the "Amended Merger Agreement") relat
Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ:AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya share will receive $0.38 per share in cash and 0.1461 shares of Quanterix common stock. With the amended exchange ratio, Quanterix will issue over 9 million fewer
SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G - Akoya Biosciences, Inc. (0001711933) (Subject)
SC 13G/A - Akoya Biosciences, Inc. (0001711933) (Subject)
425 - Akoya Biosciences, Inc. (0001711933) (Subject)
8-K - Akoya Biosciences, Inc. (0001711933) (Filer)
425 - Akoya Biosciences, Inc. (0001711933) (Subject)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
4 - Akoya Biosciences, Inc. (0001711933) (Issuer)
Joe Driscoll to Retire After More than Four Successful Years as Chief Financial Officer Johnny Ek Appointed as new Chief Financial Officer MARLBOROUGH, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that Chief Financial Officer Joe Driscoll is retiring from his position, effective March 20, 2023. Johnny Ek has been appointed as the company's new Chief Financial Officer, effective immediately. Mr. Driscoll will continue to serve as a consultant of the company as Akoya executes a seamless transition between the two leaders. Mr. Driscoll joined Akoya in April 2019 and has overseen the company's financ
MARLBOROUGH, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced the appointment of Jennifer Kamocsay as General Counsel. Ms. Kamocsay will oversee all company legal activities and provide strategic guidance and corporate governance oversight. "We are excited to welcome Jennifer to our leadership team," said Brian McKelligon, Chief Executive Officer of Akoya. "Her deep legal expertise and insight will be invaluable as we continue to advance our spatial biology platform and establish additional partnerships to support discovery, translational, and clinical markets." Ms. Kamocsay most recently served as Gen
MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company's Chief Medical Officer (CMO). In this newly created position, Dr. El-Gabry will lead Akoya's strategy in advancing the use of its spatial phenotyping solutions in the clinical setting. Dr. El-Gabry brings a wealth of experiences that are critical to the company's vision of advancing spatial phenotyping in precision medicine and cancer care. He is a board-certified pathologist who served as the Senior Medical Director for Roche Tissue Diagnostics Personalized Health Care Solutions (PHCS). As the
MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the first quarter ending March 31, 2025. "Akoya remained focused on operational discipline and innovation in the first quarter of 2025, while successfully increasing our installed base in the face of broader macroeconomic and NIH funding uncertainty. Our technology continues to gain momentum globally, underscored by growing adoption in large-scale population studies as well as an expanding publication footprint across key research areas in high-impact journals," said Brian McKelligon, CEO of Akoya Biosciences. "As we
MARLBOROUGH, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the fourth quarter and full year ending December 31, 2024. "Akoya navigated a challenging 2024 in the life science tools market, which was constrained by subdued capital equipment purchases, by successfully strengthening gross margins, reducing operating expenses and advancing our companion diagnostics programs throughout the year. We remain optimistic about the long-term growth outlook of Akoya's leading spatial biology solutions," said Brian McKelligon, CEO of Akoya. "In 2024, Akoya achieved multiple milestones, i
Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across translational, academic and pharma applications Expects to generate approximately $40 million of annual cost synergies by the end of 2026 with path to positive free cash flow generation in 2026 Combined cash position of approximately $175 million with no expected debt at closing to pursue future growth initiatives Quanterix Corporation (NASDAQ:QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ
Craig Hallum downgraded Akoya Biosciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously
Morgan Stanley downgraded Akoya Biosciences from Overweight to Equal-Weight
BTIG Research downgraded Akoya Biosciences from Buy to Neutral